New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM) system ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its latest ...
The only peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge devices, drugs, drug delivery systems, and software. In a new study in the peer-reviewed ...
Medicare Part B typically covers continuous glucose monitors (CGMs) like the Dexcom G7, as they are Food and Drug Administration (FDA)-approved durable medical equipment items. To get a Dexcom G7 CGM ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results